Biotech and Pharma Industry News | BioPharma Dive
WEBThe companies now plan on starting this year another large study of their medicine, dapirolizumab pegol, in the hopes that they can confirm its safety and effectiveness to drug regulators. BioPharma Dive provides news and analysis …
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Pharma News | BioPharma Dive
WEB3 days ago · The top biopharma conferences in 2025. Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch in 2025. By BioPharma Dive staff • Oct. 1, 2024. News roundup.
Radiopharmaceuticals for cancer: Making radiation precise
WEBAug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
Novartis wins FDA approval for new heart drug, but faces uphill …
WEBDec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400-per-year price that the Institute for Clinical and Economic Review, a watchdog group on drug costs, said would be cost effective for Leqvio when used broadly, but ...
A biotech startup gives Merck its next shot at treating Alzheimer’s
WEBPublished Aug. 9, 2022. Gwendolyn Wu Reporter. Merck & Co. will acquire an early-stage Alzheimer’s disease treatment from Boston-based Cerevance, which focuses on central nervous system diseases. Kena Betancur via Getty Images. Merck & Co. is buying into another Alzheimer’s drug, this time through a backloaded deal …
Keytruda fails lung and skin cancer trials, limiting further expansion
WEBAug 29, 2024 · Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the immunotherapy as an add-on to other types of treatment for early-stage lung and skin cancer, the comapny said Thursday. Both trials were stopped early following the recommendation of independent data analysts, who …
Biotech News - BioPharma Dive
WEB3 days ago · With $115M more, Triveni accelerates immune drug work. The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year. By Gwendolyn Wu • Oct. 2, 2024.
A gene editing biotech’s struggles end with reverse merger
WEBNov 15, 2023 · Graphite Bio has agreed to a reverse merger with Lenz Therapeutics, ending a yearslong odyssey of ups and downs for the once-promising gene editing company. Under the terms of the agreement, Graphite shareholders will end up with about 35% of the new company, which will be renamed Lenz Therapeutics and trade on the Nasdaq stock exchange under ...
Medicare reveals results of drug price negotiations
WEBAug 15, 2024 · According to CMS, the negotiated prices for the 10 drugs range from 38% to 79% lower, on average, than the medicines’ current wholesale acquisition cost, or list price set by drugmakers. Paying these new rates should save Medicare enrollees an estimated $1.5 billion in out-of-pocket costs in 2026, CMS said. Determining the government’s ...